GC Biopharma net profit surges 1,051.9% on Curevo stake sale
AI Summary- GC Biopharma reported third-quarter revenue of 522.1 billion won and operating profit of 49.2 billion won.
- Net profit rose 1,051.9% to 208.5 billion won, reflecting a 290 billion won Curevo-related payment.
- Alyglo sales reached $46 million, while global Phase 1/2 trials for the licensed candidate continued.